OSTX enters its May 22 earnings event with a fresh analyst target reduction arriving just days before the print — a cautious signal against a backdrop of strong recent price momentum.
Lake Street trimmed its price target on OSTX to $13 from $14 yesterday, while holding its Buy rating. The cut is modest but the timing matters: it arrives as the stock trades near $1.76, a level that sits far below even the revised target. D. Boral Capital has repeatedly maintained a $20 Buy through multiple reiterations this year. The mean analyst target of $11.52 implies substantial upside from current levels, though the gap between targets and price reflects the speculative nature of the setup — this is a pre-profitability biotech where investors are pricing in binary outcomes, not current fundamentals.
The bull case centres on OST-HER2's regulatory progress. The EMA has initiated a rolling review, and the pipeline of catalysts — an overall survival update, an RMAT decision, and a potential BLA submission in the second half of 2026 — gives bulls a clear roadmap to value creation. The Priority Review Voucher remains a potential non-dilutive funding mechanism. Bears point to slipping timelines: key regulatory meetings and global Phase 3 initiation have been pushed to Q2 and Q3 2026. With no new clinical readouts expected near-term and the company burning cash, financing concerns are never far from the surface for a name with no revenue and an EV around $65 million.
Short positioning has ticked higher heading into the event. Short interest climbed 13% over the past week to roughly 3.8% of the free float — not extreme territory, but the directional move is notable. Borrowing costs remain contained at around 2%, and availability has loosened considerably from its tightest recent levels. Earlier this month, availability compressed toward 49%, suggesting a brief squeeze on borrow supply. It has since opened back up to 116%, meaning there is now more than one share available to borrow for every share already short — conditions that do not point to imminent squeeze pressure.
The print will test whether the company can demonstrate meaningful progress against its regulatory timeline, and whether the pace of cash consumption remains compatible with the funding runway — the two variables that divide bulls and bears most sharply on this name.
See the live data behind this article on ORTEX.
Open OSTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
